Leqembi

Lecanemab, the active ingredient in Leqembi, is a monoclonal antibody presented as an intravenous infusion for intravenous use. It treats early symptomatic Alzheimer’s disease in patients with mild cognitive impairment or mild dementia. GNH USA supplies Leqembi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leqembi (lecanemab) is an anti‑amyloid disease‑modifying therapy used in the management of Alzheimer’s disease.

Alzheimer’s disease (early symptomatic): reduces amyloid plaque burden and may slow cognitive decline in patients with mild cognitive impairment or mild dementia. Alzheimer’s disease (mild dementia): supports disease modification by targeting soluble aggregated amyloid‑beta species.

Leqembi may be associated with a range of adverse reactions observed in clinical use.

Common Side Effects: - Infusion‑related reactions (e.g., flushing, chills, rash) - Headache - Dizziness - Nausea - Edema - Arthralgia

Serious or Rare Side Effects: - Amyloid‑related imaging abnormalities (ARIA‑E or ARIA‑H) - Severe hypersensitivity or anaphylaxis - Cerebral edema or microhemorrhage - Severe infusion reactions requiring medical intervention - Thromboembolic events - Acute respiratory distress syndrome

Leqembi requires careful monitoring due to its mechanism and potential adverse events. - MRI monitoring: Perform baseline and periodic MRI to detect ARIA. - Hypersensitivity: Assess for prior allergic reactions before infusion. - Anticoagulant use: Evaluate bleeding risk when combined with anticoagulants. - Specialist supervision: Administration should be overseen by clinicians experienced in biologic therapies. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Leqembi may interact with other agents that affect amyloid pathology or bleeding risk.

Major Interactions (Avoid): - Other anti‑amyloid monoclonal antibodies: additive risk of ARIA. - Anticoagulants/antiplatelet agents: may increase cerebral microhemorrhage.

Moderate Interactions (Monitor Closely): - Live vaccines: monitor immune response post‑vaccination. - Immunosuppressants: may reduce therapeutic efficacy. - Renal impairment: monitor for fluid overload during infusion. - Concomitant CNS‑active drugs: observe for additive dizziness or headache.